Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present at the AACR Annual Meeting 2026

VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
April 14, 2026 08:00 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH

Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
April 14, 2026 08:00 ET | Source: LIS Technologies Inc.

LIS Technologies Inc., Developer of the Only U.S. Origin and Patented Technology for Laser Uranium Enrichment, Announces its Platinum Sponsorship and Executives’ Participation in the World Nuclear Fuel Cycle 2026

Oak Ridge, Tennessee, April 14, 2026 (GLOBE NEWSWIRE) -- LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented...
April 14, 2026 08:00 ET | Source: BioVie, Inc.

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...
April 14, 2026 07:30 ET | Source: Anavex Life Sciences Corp.

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease

Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across...
April 14, 2026 07:00 ET | Source: Adagene Inc.

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...
April 14, 2026 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...
April 14, 2026 06:00 ET | Source: AtaiBeckley Inc.

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by...
April 13, 2026 18:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Provides Routine Update on Annual Filings

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year...
April 13, 2026 16:30 ET | Source: Cellectis Inc.

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform...